

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Ticagrelor

March 17, 2026

### **Therapeutic category**

Other agents relating to blood and body fluids

### **Non-proprietary name**

Ticagrelor

### **Safety measure**

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.  
 This English version is intended to be a reference material to provide convenience for users.  
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)  2.5 Patients receiving a strong CYP3A inhibitor (itraconazole, voriconazole, clarithromycin, ritonavir, preparations containing cobicistat, ensitrelvir fumaric acid)			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)  2.5 Patients receiving a strong CYP3A inhibitor (itraconazole, voriconazole, clarithromycin, ritonavir, preparations containing cobicistat, ensitrelvir fumaric acid, <u>ceritinib</u> )		
10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)			10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Strong CYP3A inhibitors Itraconazole Voriconazole Clarithromycin Ritonavir Preparations containing cobicistat Ensitrelvir fumaric acid	The platelet aggregation inhibition by this drug may be enhanced.	These drugs are expected to inhibit the metabolism of this drug by strongly inhibiting CYP3A, leading to a marked increase in plasma concentrations of this drug.	Strong CYP3A inhibitors Itraconazole Voriconazole Clarithromycin Ritonavir Preparations containing cobicistat Ensitrelvir fumaric acid <u>Ceritinib</u>	The platelet aggregation inhibition by this drug may be enhanced.	These drugs are expected to inhibit the metabolism of this drug by strongly inhibiting CYP3A, leading to a marked increase in plasma concentrations of this drug.